This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Adenocarcinoma Pancreas
and you are
over 18
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

This is a pilot study to evaluate the role of the addition of CP870, 893 to the neoadjuvant and adjuvant setting for patients with resectable pancreatic cancer. Patients will receive standard surgery followed by chemoradiation for their disease, but one dose of gem/cp 870,893 will be pre-op and 3 doses post-op.

Provided treatments

  • Other: Gemcitabine
  • Drug: CP-870,893

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01456585. The sponsor of the trial is Abramson Cancer Center of the University of Pennsylvania and it is looking for 10 volunteers for the current phase.
Official trial title:
Phase 1 Study of Preoperative Gemcitabine Plus CP-870,893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patient With Newly Diagnosed Resectable Pancreatic Carcinoma